Caplin Point Laboratories Limited share price
NSE: CAPLIPOINT · ISIN INE475E01026
Key numbers
- Market cap
- ₹ 21,550 Cr
- Current price
- ₹ 2,835.10
- 52-week high / low
- ₹ 2,990 / 1,500
- Stock P/E
- 32.9
- Book value
- ₹ 462.0
- Dividend yield
- 0.28%
- ROCE
- 24.9%
- ROE
- 19.9%
- Debt to equity
- 0.00
- Sales growth (3 yrs)
- 14.3%
- Profit growth (3 yrs)
- 19.4%
- 1-year return
- 25.8%
About Caplin Point Laboratories Limited
Caplin Point Laboratories Limited, together with its subsidiaries, engages in the development, production, marketing, and export of generic formulations and branded products in India. The company provides tablets, capsules, injections, ophthalmic, liquid orals, softgel capsules, ointments, creams and gels, powder for injections, suppositories, ovules, pre-mix bag formulations, inhalers, and sprays and IV infusion. It also provides dry and syrups, lyophilized vials, prefilled syringes, emulsion injection, sachets, liquid injectables, topicals, pre-filled syringes, and pre-mix bags. Caplin Point Laboratories Limited was incorporated in 1990 and is headquartered in Chennai, India.
Quarterly results
Consolidated figures in ₹ crores
| Mar 2025 | Jun 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 502 | 510 | 543 | 600 | 610 |
| Operating profit | 168 | 178 | 190 | 204 | 213 |
| Net profit | 143 | 153 | 164 | 170 | 177 |
| EPS (₹) | 18.75 | 20.10 | 21.56 | 22.38 | 23.27 |
Investor presentation summary (2026-08-12)
AI summary of the presentation · tone: Positive · source document
Key numbers
- EBITDA Margin % 38.4% 37.7% 37.0% 38.1% 36.5%
- PAT Margin 27.8% 28.3% 27.5% 28.2% 26.6%
Guidance & outlook
- Gross Margin stands at 59.8% for Q1 FY27 as compared to 61.7% in Q1 FY26.
- ITDA Margin for Q1 FY27 is at 38.4% vs 37.7% in Q1 FY26.
Growth & demand
- to launch these products in the coming months. The company is working on a pipeline of 120+ products to
- Amaris Clinical update – To cater to growing demands for internal pipeline products BE and Clinical
Margins & costs
- Gross Margin % 59.8% 61.7% 59.2% 60.4% 60.2%
- PBT Margin % 35.0% 34.6% 34.0% 34.9% 33.3%
Capex & expansion
- Free Cash Flow is ₹40 Crores (after Capex investment of ₹55 Crores) in Q1 FY27 as compared to ₹53 Crores
- (after capex investment of ₹65 Crores) in Q1 FY26.
Peers in Drug Manufacturers - Specialty & Generic
Data for information only, not investment advice. Prices end of day.